Mixed nanomicelles as potential carriers for systemic delivery of Z-GP-Dox, an FAPα-based doxorubicin prodrug: Formulation and pharmacokinetic evaluation

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 1625-1636

  Zhang, Yuchen ^a   Zhang, Xingwang ^a   Liu, Hongming ^a   Cai, Shaohui ^a   Wu, Baojian ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

Doxorubicin; Micelles; Pharmacokinetics; Physiologically based pharmacokinetic model; Systemic delivery; Z GP Dox

Indexed keywords

DOXORUBICIN; DRUG CARRIER; N TERMINAL CARBOBENZOXY GLYCYL PROLINE 4 BLOCKED DIPEPTIDE DERIVATIVE OF DOXORUBICIN; NANOMICELLE; PRODRUG; UNCLASSIFIED DRUG; GELATINASE; MEMBRANE PROTEIN; MICELLE; NANOPARTICLE; SEPRASE; SERINE PROTEINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DATA ANALYSIS; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG STABILITY; DRUG STRUCTURE; HEART; INTESTINE; KIDNEY PARENCHYMA; LIVER; LUNG PARENCHYMA; MALE; MEAN RESIDENCE TIME; NONHUMAN; PHYSICAL CHEMISTRY; RAT; SPLEEN; TISSUE DISTRIBUTION; ANIMAL; CHEMISTRY; MICELLE;

RATTUS;

ANIMALS; DOXORUBICIN; DRUG CARRIERS; GELATINASES; MEMBRANE PROTEINS; MICELLES; NANOPARTICLES; PRODRUGS; RATS; SERINE ENDOPEPTIDASES; TISSUE DISTRIBUTION;

EID: 84924284898     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S75954     Document Type: Article

References (34)

1. Christiansen VJ, Jackson KW, Lee KN, Downs TD, McKee PA. Targeting inhibition of fibroblast activation protein-alpha and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments. Neoplasia. 2013;15(4):348-358.
2. Huang S, Fang R, Xu J, et al. Evaluation of the tumor targeting of a FAPα-based doxorubicin prodrug. J Drug Target. 2011;19(7):487-496.
3. Liu XL, Lynn BC, Zhang JH, et al. A versatile prodrug approach for liposomal core-loading of water-insoluble camptothecin anticancer drugs. J Am Chem Soc. 2002;124(26):7650-7651.
4. Gupta S. Biocompatible microemulsion systems for drug encapsulation and delivery. Curr Sci. 2011;101(2):174-188.
5. Dutta P, Dey J. Drug solubilization by amino acid based polymeric nanoparticles: characterization and biocompatibility studies. Int J Pharm. 2011;421(2):353-363.
6. Zhang X, Zhang X, Yu P, Han Y, Li Y, Li C. Hydrotropic polymeric mixed micelles based on functional hyperbranched polyglycerol copolymers as hepatoma-targeting drug delivery system. J Pharm Sci. 2013;102(1):145-153.
7. Gill KK, Kaddoumi A, Nazzal S. Mixed micelles of PEG(2000)-DSPE and vitamin-E TPGS for concurrent delivery of paclitaxel and parthenolide: enhanced chemosenstization and antitumor efficacy against non-small cell lung cancer (NSCLC) cell lines. Eur J Pharm Sci. 2012;46(1-2):64-71.
8. Li J, Huo MR, Wang J, et al. Redox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel. Biomaterials. 2012;33(7):2310-2320.
9. Saxena V, Hussain MD. Formulation and in vitro evaluation of 17-allyamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric mixed micelles for glioblastoma multiforme. Colloids Surf B Biointerfaces. 2013;112:350-355.
10. Saxena V, Hussain MD. Polymeric mixed micelles for delivery of curcumin to multidrug resistant ovarian cancer. J Biomed Nanotechnol. 2013;9(7):1146-1154.
11. Chen Y, Zhang W, Gu J, et al. Enhanced antitumor efficacy by methotrexate conjugated Pluronic mixed micelles against KBv multidrug resistant cancer. Int J Pharm. 2013;452(1-2):421-433.
12. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev. 2001;47(1):113-131.
13. Song X, Jiang Y, Ren CJ, et al. Nimodipine-loaded mixed micelles: formulation, compatibility, pharmacokinetics, and vascular irritability study. Int J Nanomedicine. 2012;7:3689-3699.
14. Mehta SK, Jindal N. Mixed micelles of lecithin-Tyloxapol as pharmaceutical nanocarriers for anti-tubercular drug delivery. Colloids Surf B Biointerfaces. 2013;110:419-4425.
15. Hammad MA, Muller BW. Increasing drug solubility by means of bile salt-phosphatidylcholine-based mixed micelles. Eur J Pharm Biopharm. 1998;46(3):361-367.
16. Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol. 2011;51:45-73.
17. Atkinson AJ, Smith BP. Models of physiology and physiologically based models in clinical pharmacology. Clin Pharmacol Ther. 2012;92(1):3-6.
18. Chow EC, Pang KS. Why we need proper PBPK models to examine intestine and liver oral drug absorption. Curr Drug Metab. 2013;14(1):57-79.
19. Pang KS, Durk MR. Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion. J Pharmacokinet Pharmacodyn. 2010;37(6):591-615.
20. Rostami-Hodjegan A. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther. 2012;92(1):50-61.
21. Kagan L, Gershkovich P, Wasan KM, Mager DE. Dual physiologically based pharmacokinetic model of liposomal and nonliposomal amphotericin B disposition. Pharm Res. 2014;31(1):35-45.
22. Ren TY, Cong L, Wang, et al. Lipid emulsions in parenteral nutrition: current applications and future developments. Expert Opin Drug Deliv. 2013;10(11):1533-1549.
23. Zhang X, Zhang T, Zhou X, et al. Enhancement of oral bioavailability of tripterine through lipid nanospheres: preparation, characterization, and absorption evaluation. J Pharm Sci. 2014;103(6):1711-1719.
24. Mano N, Mao F, Heller A. A miniature biofuel cell operating in a physiological buffer. J Am Chem Soc. 2002;124(44):12962-12963.
25. Liu H, Sun H, Lu D, et al. Identification of glucuronidation and biliary excretion as the main mechanisms for gossypol clearance: in vivo and in vitro evidence. Xenobiotica. 2014;44(8):696-707.
26. Liu W, Liu H, Sun H, et al. Metabolite elucidation of the Hsp90 inhibitor SNX-2112 using ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS). Xenobiotica. 2014;44(5):455-464.
27. Kagan L, Gershkovich P, Wasan KM, Mager DE. Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone®): pooled analysis of published data. AAPS J. 2011;13(2):255-264.
28. Mayer LD, Tai LC, Ko DS, et al. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res. 1989;49(21):5922-5930.
29. Nie S. Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine (Lond). 2010;5(4):523-528.
30. Cho YW, Lee J, Lee SC, Huh KM, Park K. Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles. J Control Release. 2004;97(2):249-257.
31. Agrawal SK, Sanabria-DeLong N, Coburn JM, Tew GN, Bhatia SR. Novel drug release profiles from micellar solutions of PLA-PEO-PLA triblock copolymers. J Control Release. 2006;112(1):64-71.
32. Guo S, Huang L. Nanoparticles escaping RES and endosome: challenges for siRNA delivery for cancer therapy. J Nanomater. 2011;2011:1-12.
33. Hassan MH, Ghobara M, Abd-Allah GM. Modulator effects of meloxicam against doxorubicin-induced nephrotoxicity in mice. J Biochem Mol Toxicol. 2014;28(8):337-346.
34. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2013;65(1):71-79.